Effects of a monthly injectable steroidal contraceptive, Mesigyna, on menstrual pattern, lipoproteins, and coagulation parameters.
The objective of this study was to determine the effects of a once-monthly injectable contraceptive (Mesigyna) on menstrual pattern, lipoproteins, and coagulation parameters. Thirty-six women aged 18-35 years requesting monthly injectable contraception were included. Before injecting estradiol valerate 5 mg and norethisterone enanthate 50 mg, coagulation, lipoprotein, and liver function parameters were determined. After the 3- and 6-month injections, the same coagulation and serum lipid measurements and liver function tests were repeated, and women were questioned about their menstrual patterns and side effects. Thirty women who completed 6 months were evaluated. At the end of 3 months, two-thirds of the 30 women had normal menstrual patterns; at the end of 6 months, 80% of the women had normal menses. Serum LDL, total cholesterol, and triglyceride levels did not change significantly, while HDL and VLDL decreased significantly (p = 0.032 and p = 0.039, respectively) at 6 months. PT and aPTT measures did not change at the end of 6 months, while fibrinogen levels were significantly lower (p = 0.013). Serum total bilirubin levels increased (p = 0.022) and albumin levels decreased (p = 0.022) at the end of 6 months. Mesigyna was well tolerated and side effects and menstrual abnormalities were acceptable. There were no clinically significant changes in lipoprotein, coagulation, or hepatic parameters.
Bulent Tiras
M
M
Gazi University School of Medicine; Dept. of Obstetrics and Gynecology, Ankara, Turkey.
Noyan
V
V
Fener
N
N
Guner
H
H
Yildirim
M
M
Darney
P D
PD
D000293:Adolescent; D000328:Adult; D001663:Bilirubin / Q000097:blood; D001777:Blood Coagulation / Q000187:drug effects*; D002784:Cholesterol / Q000097:blood; D003271:Contraceptive Agents, Female / Q000008:administration & dosage / Q000009:adverse effects*; D004338:Drug Combinations; D004958:Estradiol / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D006801:Humans; D007267:Injections; D008074:Lipoproteins / Q000097:blood*; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008079:Lipoproteins, VLDL / Q000097:blood; D008598:Menstruation / Q000187:drug effects*; D009640:Norethindrone / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives; D010314:Partial Thromboplastin Time; D011517:Prothrombin Time; D012709:Serum Albumin / Q000032:analysis; D014280:Triglycerides / Q000097:blood
D003271:Contraceptive Agents, Female; D004338:Drug Combinations; D008074:Lipoproteins; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D012709:Serum Albumin; D014280:Triglycerides; C418365:estradiol, norethindrone drug combination; D004958:Estradiol; D005340:Fibrinogen; D002784:Cholesterol; D001663:Bilirubin; D009640:Norethindrone